Cargando…

Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study

Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body com...

Descripción completa

Detalles Bibliográficos
Autores principales: Volpe, Sara, Lisco, Giuseppe, Racaniello, Davide, Fanelli, Margherita, Colaianni, Valentina, Vozza, Alfredo, Triggiani, Vincenzo, Sabbà, Carlo, Tortorella, Cosimo, De Pergola, Giovanni, Piazzolla, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227575/
https://www.ncbi.nlm.nih.gov/pubmed/35745144
http://dx.doi.org/10.3390/nu14122414
_version_ 1784734217104523264
author Volpe, Sara
Lisco, Giuseppe
Racaniello, Davide
Fanelli, Margherita
Colaianni, Valentina
Vozza, Alfredo
Triggiani, Vincenzo
Sabbà, Carlo
Tortorella, Cosimo
De Pergola, Giovanni
Piazzolla, Giuseppina
author_facet Volpe, Sara
Lisco, Giuseppe
Racaniello, Davide
Fanelli, Margherita
Colaianni, Valentina
Vozza, Alfredo
Triggiani, Vincenzo
Sabbà, Carlo
Tortorella, Cosimo
De Pergola, Giovanni
Piazzolla, Giuseppina
author_sort Volpe, Sara
collection PubMed
description Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body composition in patients with T2D. Methods: Forty patients with T2D were treated with subcutaneous Semaglutide and evaluated at the baseline (T0) and after three (T3) and six (T6) months. Body composition was assessed by a phase-sensitive bioimpedance analyzer. Visceral adipose tissue (VAT) thickness was also measured with an ultrasonographic method (US-VAT). Anthropometric variables, muscular strength, and laboratory tests were analyzed and compared. Results: A significant decrease in VAT, the fat mass index (FMI), and BW loss was observed at all observation times. US-VAT, the skeletal mass index (SMI), the fat-free mass index (FFMI), waist circumferences, and glycated hemoglobin had lessened after three months and remained stable at T6. No variations in muscle strength, the muscle quality index, and body water were found. Discussion: In a real-life setting, Semaglutide provided significant weight loss mainly due to a reduction in the FMI and VAT, with non-clinically relevant changes in the SMI, the FFMI, and muscle strength. Most importantly, the results were obtained after three months of treatment and persisted thereafter.
format Online
Article
Text
id pubmed-9227575
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92275752022-06-25 Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study Volpe, Sara Lisco, Giuseppe Racaniello, Davide Fanelli, Margherita Colaianni, Valentina Vozza, Alfredo Triggiani, Vincenzo Sabbà, Carlo Tortorella, Cosimo De Pergola, Giovanni Piazzolla, Giuseppina Nutrients Article Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body composition in patients with T2D. Methods: Forty patients with T2D were treated with subcutaneous Semaglutide and evaluated at the baseline (T0) and after three (T3) and six (T6) months. Body composition was assessed by a phase-sensitive bioimpedance analyzer. Visceral adipose tissue (VAT) thickness was also measured with an ultrasonographic method (US-VAT). Anthropometric variables, muscular strength, and laboratory tests were analyzed and compared. Results: A significant decrease in VAT, the fat mass index (FMI), and BW loss was observed at all observation times. US-VAT, the skeletal mass index (SMI), the fat-free mass index (FFMI), waist circumferences, and glycated hemoglobin had lessened after three months and remained stable at T6. No variations in muscle strength, the muscle quality index, and body water were found. Discussion: In a real-life setting, Semaglutide provided significant weight loss mainly due to a reduction in the FMI and VAT, with non-clinically relevant changes in the SMI, the FFMI, and muscle strength. Most importantly, the results were obtained after three months of treatment and persisted thereafter. MDPI 2022-06-10 /pmc/articles/PMC9227575/ /pubmed/35745144 http://dx.doi.org/10.3390/nu14122414 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Volpe, Sara
Lisco, Giuseppe
Racaniello, Davide
Fanelli, Margherita
Colaianni, Valentina
Vozza, Alfredo
Triggiani, Vincenzo
Sabbà, Carlo
Tortorella, Cosimo
De Pergola, Giovanni
Piazzolla, Giuseppina
Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
title Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
title_full Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
title_fullStr Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
title_full_unstemmed Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
title_short Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
title_sort once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: a 26-week prospective real-life study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227575/
https://www.ncbi.nlm.nih.gov/pubmed/35745144
http://dx.doi.org/10.3390/nu14122414
work_keys_str_mv AT volpesara onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT liscogiuseppe onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT racaniellodavide onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT fanellimargherita onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT colaiannivalentina onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT vozzaalfredo onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT triggianivincenzo onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT sabbacarlo onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT tortorellacosimo onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT depergolagiovanni onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy
AT piazzollagiuseppina onceweeklysemaglutideinducesanearlyimprovementinbodycompositioninpatientswithtype2diabetesa26weekprospectivereallifestudy